<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04962230</url>
  </required_header>
  <id_info>
    <org_study_id>C4671014</org_study_id>
    <nct_id>NCT04962230</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With Ritonavir</brief_title>
  <official_title>A PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD CROSSOVER STUDY TO ESTIMATE THE EFFECT OF CARBAMAZEPINE ON THE PHARMACOKINETICS OF PF-07321332 BOOSTED WITH RITONAVIR IN HEALTHY PARTICIPANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a drug-drug interaction study to assess the effects of a single dose of&#xD;
      PF-07321332/ritonavir after multiple dose administrations of carbamazepine. Pharmacokinetic&#xD;
      (PK) will be evaluated for PF-07321332 and ritonavir. Carbamazepine is being utilized as a&#xD;
      cytochrome P450 3A4 (CYP3A4) inducer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 15, 2021</start_date>
  <completion_date type="Actual">October 9, 2021</completion_date>
  <primary_completion_date type="Actual">October 9, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a Phase 1, fixed sequence, 2-period study to estimate the effect of a strong CYP3A4 inducer, carbamazepine, on the PK of PF-07321332 and ritonavir in healthy participants. A total of approximately 12 healthy male and/or female participants will be enrolled into the study.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of PF-07321332/ritonavir when administered alone</measure>
    <time_frame>Period 1 - Day 1 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, and 48 hour post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of PF-07321332/ritonavir when administered with carbamazepine</measure>
    <time_frame>Period 2 - Day 14 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, and 48 hour post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of PF-07321332/ritonavir when administered alone</measure>
    <time_frame>Period 1 - Day 14 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, and 48 hour post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of PF-07321332/ritonavir when administered with carbamazepine</measure>
    <time_frame>Period 2 - Day 1 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, and 48 hour post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of PF-07321332/ritonavir</measure>
    <time_frame>Period 2 - Day 14 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, and 48 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of PF-07321332/ritonavir</measure>
    <time_frame>Period 2 - Day 14 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, and 48 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Participants With Treatment-Emergent Adverse Events (TEAEs) of PF-07321332/Ritonavir</measure>
    <time_frame>Days 1-15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Participants With Abnormalities in Physical Examination (PE) of PF-07321332/Ritonavir</measure>
    <time_frame>Days 1-15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities of PF-07321332/Ritonavir</measure>
    <time_frame>Days 1-15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Participants With Clinically Significant Change From Baseline in Vital Signs of PF-07321332/Ritonavir</measure>
    <time_frame>Days 1-15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings of PF-07321332/Ritonavir</measure>
    <time_frame>Days 1-15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-07321332/ritonavir when administered alone</measure>
    <time_frame>Period 1 - Day 1 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, and 48 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of PF-07321332/ritonavir when administered with carbamazepine</measure>
    <time_frame>Period 2 - Day 14 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, and 48 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-07321332/ritonavir when administered alone</measure>
    <time_frame>Period 1 - Day 1 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, and 48 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of PF-07321332/ritonavir when administered with carbamazepine</measure>
    <time_frame>Period 2 - Day 14 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, and 48 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F) of PF-07321332/ritonavir when administered alone</measure>
    <time_frame>Period 1 - Day 1 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, and 48 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of PF-07321332/ritonavir when administered with carbamazepine</measure>
    <time_frame>Period 2 - Day 14 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, and 48 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of PF-07321332/ritonavir when administered alone</measure>
    <time_frame>Period 1 - Day 1 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, and 48 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F of PF-07321332/ritonavir when administered with carbamazepine</measure>
    <time_frame>Period 2 - Day 14 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, and 48 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) of PF-07321332/ritonavir when administered alone</measure>
    <time_frame>Period 1 - Day 1 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, and 48 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of PF-07321332/ritonavir when administered with carbamazepine</measure>
    <time_frame>Period 2 - Day 14 pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, and 48 hour post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Participant</condition>
  <arm_group>
    <arm_group_label>Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07321332/ritonavir orally as a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carbamazepine + PF-07321332/ritonavir orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-07321332/ritonavir</intervention_name>
    <description>PF-07321332/ritonavir administered orally as a single dose on Day 1, Period 1</description>
    <arm_group_label>Period 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbamazepine</intervention_name>
    <description>In Period 2, Days 1-3, participants will receive low-dose of carbamazepine twice daily (BID), then a titrated mid-dose of carbamazepine BID on Days 4-7, and finally maintaining carbamazepine at the high-dose on Days 8-15.</description>
    <arm_group_label>Period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF 07321332/ritonavir</intervention_name>
    <description>In Period 2, Day 14, participants will receive a single dose of PF-07321332/ritonavir orally.</description>
    <arm_group_label>Period 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female participants of childbearing potential must have a negative (urine or serum)&#xD;
             pregnancy test.&#xD;
&#xD;
          2. Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lb).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive test reverse-transcriptase polymerase chain reaction (RT-PCR) result for&#xD;
             SARS-CoV-2 infection at the time of Screening or Day -1.&#xD;
&#xD;
          2. Subjects shown to carry or be positive for human leukocyte antigen (HLA)-B*1502 and&#xD;
             HLA-A*3101&#xD;
&#xD;
          3. Participants taking monoamine oxidase inhibitors (MAOIs) should discontinue MAOI for a&#xD;
             minimum of 14 days prior to dosing in the current study.&#xD;
&#xD;
          4. Hormonal methods of contraception (including oral and transdermal contraceptives,&#xD;
             injectable progesterone, vaginal ring, and postcoital contraceptive methods) and&#xD;
             hormone replacement therapy must have been discontinued at least 28 days prior to the&#xD;
             first dose of investigational product. Depo Provera must be discontinued at least 6&#xD;
             months prior to the first dose of study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C4671014</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <reference>
    <citation>Andreasen AH, Brøsen K, Damkier P. A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4. Epilepsia. 2007 Mar;48(3):490-6.</citation>
    <PMID>17346248</PMID>
  </reference>
  <results_reference>
    <citation>Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 1998 Oct;35(4):275-91. Review. Erratum in: Clin Pharmacokinet 1998 Dec;35(6):473.</citation>
    <PMID>9812178</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 10, 2021</study_first_submitted>
  <study_first_submitted_qc>July 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-drug interaction</keyword>
  <keyword>Carbamazepine</keyword>
  <keyword>CYP3A4 inducer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Carbamazepine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

